<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5090660 Figure_1-B</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 1-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Hematoxylin and eosin staining (H&amp;E) of skeletal muscle from patient II.1 shows histological features of moderate to severe dystrophic pattern. (Scale bar, 50 &#956;m).</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_1-C</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>C T1-weighted MRI axial images at thigh and calf levels show that the fatty degeneration is more prominent in thigh muscles, equally affecting posterior and anterior compartment, with relative sparing of the rectus femoris, sartorius and gracilismuscles until late stages (4, 10 and 11, respectively). Strikingly, the fatty tissue is located in the internal parts of almost all the affected muscles in thigh (1, 2, 3, 5-9), while the external regions are spared. At calf level, only the gastrocnemius medialis muscle (12) shows this pattern, while the soleus (13) is diffusely involved. Patient II.2 (PII.2) shows late-stage thigh muscles with an unusual involvement of the tibialis posteriormuscle (14) in the lower leg.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_2-A</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 2-A</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A</infon>
    <passage>
      <offset>0</offset>
      <text>A Muscle sections show variable labeling using an antibody against glycosylated &#945;-dystroglycan (&#945;DG-IIH6), whereas labeling using antibodies against &#945;-dystroglycan core protein (&#945;DG-Core), &#946;-dystroglycan (&#946;DG) and laminin-2 is similar to control (Scale bar, 100 &#956;m).</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_2-B</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 2-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-B</infon>
    <passage>
      <offset>0</offset>
      <text>B Western blots and ligand-overlay (O/L) of wheat-germ agglutinin-enriched muscle and fibroblasts lysates from PII.2, PII.5, the healthy sibling (HII.3) and healthy controls (Ctr, Ctr1, and Ctr2) (Muscle: 250&#956;g protein/lane, Fibroblasts: 800&#956;g/lane). In muscle, expression of &#945;DG-IIH6 is reduced but the &#945;DG-Core shows similar expression as controls, with a slight reduction in molecular weight; laminin overlay assay detected some binding activity but was diminished compared to controls, whereas agrin-binding activity showed no difference with controls. In fibroblasts, both &#945;DG-IIH6 and &#945;DG-Core expression and laminin-binding activity were normal, suggesting that unlike other muscular dystrophies, &#945;-dystroglycan glycosylation defect is muscle-specific in POGLUT1 patients.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_2-C</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 2-C</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C</infon>
    <passage>
      <offset>0</offset>
      <text>C No ultrastructural alterations are observed in muscle by electron microscopy (6-7 fields were captured from PII.1, PII.3, and PII.5). Note normal basement membrane compactation (arrowheads). Original magnification: 26,700.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_4-A</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 4-A</infon>
    <infon key="sourcedata_figure_dir">Figure_4-A</infon>
    <passage>
      <offset>0</offset>
      <text>A Protein O-glucosyltransferase activity of wild-type (WT) or D233E mutant POGLUT1 protein toward human factor IX EGF repeat (hFIX-EGF). Wild-type shows higher O-glucosyltransferase activity than D233E, and this activity is dependent on the concentration of the acceptor substrate hFIX-EGF repeat (left) and on the concentration of donor substrate UDP-glucose (UDP-Glc) (right). Values indicate mean &#177; SEM from three independent assays.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_4-B</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 4-B</infon>
    <infon key="sourcedata_figure_dir">Figure_4-B</infon>
    <passage>
      <offset>0</offset>
      <text>B O-glucosyltransferase activity towards five different single EGF repeats from mouse Notch1. Wild-type POGLUT1 shows higher activity toward all EGF repeats tested than POGLUT1D233E. The Y-axis shows the normalized activity relative to wild-type POGLUT1. EGF repeats were at 10 &#956;M. Values indicate mean &#177; SEM from three independent assays.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_4-C</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 4-C</infon>
    <infon key="sourcedata_figure_dir">Figure_4-C</infon>
    <passage>
      <offset>0</offset>
      <text>C Elution profiles of the POGLUT1 reaction products on reverse phase HPLC. hFIX-EGF repeat was incubated with wild-type or D233E mutant POGLUT1 and donor substrate, UDP-Glc or UDP-xylose (UDP-Xyl), at 37&#186;C overnight. Values on top of the peaks indicate the measured masses. Addition of Glc (162 Da) or xylose (132 Da) to hFIX-EGF (5696.2 Da) by wild-type POGLUT1 caused a shift to an earlier retention time (left). Similarly, the products exhibited a similar shift after incubation with POGLUT1D233E (right). These results indicate that POGLUT1D233E can add a single glucose or xylose to hFIX-EGF repeats and thus has residual enzymatic activity.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_5-A</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 5-A</infon>
    <infon key="sourcedata_figure_dir">Figure_5-A</infon>
    <passage>
      <offset>0</offset>
      <text>A Western blot of muscle homogenates shows reduced expression of Notch1 intracellular domain (NICD) in patients.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_5-B-C</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 5-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_5-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>B-C qRT-PCR on RNA extracted from skeletal-muscle shows that expression of HES1 (B) and PAX7 (C) was significantly lower in D233E patients compared to healthy controls. Mean &#177; SEM, Student&#180;s t-test (B) and Mann-Whitney U test (C).</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_5-D</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 5-D</infon>
    <infon key="sourcedata_figure_dir">Figure_5-D</infon>
    <passage>
      <offset>0</offset>
      <text>D PAX7+ cells in skeletal muscle sections, demonstrating that satellite cells are less abundant in D233E patients than in controls (n = 3 muscles with 10-15 fields analyzed per muscle). Mean &#177; SEM; Mann-Whitney U test; Scale bar, 50 &#956;m.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_6-A-H</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 6-A-H</infon>
    <infon key="sourcedata_figure_dir">Figure_6-A-H</infon>
    <passage>
      <offset>0</offset>
      <text>A-A" Staining of Drosophila indirect flight muscles at 25% pupal development with 22C10 antibody (myotube marker) and anti-Twist antibody (myoblast marker) indicates that in wild-type animals, indirect flight muscles are formed from 6 myotubes, and a large number of Twist+myoblasts are present. B-B" rumi79/79 mutants raised at 18C show no obvious defects in myoblast number or myotube morphology. C-D" rumi79/79 mutants exhibit decreased number of myoblasts at 25&#176;-30&#176;C and either an incomplete set of short myotubes when raised at 25C or aberrant morphology of myotubes when raised at 30C. E-E" rumi79/79 animals overexpressing FLAG-tagged POGLUT1WT in the muscle compartment using Mef2-GAL4 and raised at 25C during the pupal stage show a rescue of the rumi79/79 muscle phenotype. F-G" Overexpression of FLAG-tagged POGLUT1D233E only partially rescues the rumi79/79 muscle phenotype, with some variation in the myotube length and the number of restored Twist+cells (compare G and F). Note that the number of Twist+cells restored by POGLUT1D233E is much smaller than that restored by POGLUT1WT. Scale bar in A' is 50 &#181;m and applies to A-G". H Quantification of myotube lengths in rumi79/79 mutants with or without POGLUT1 expression indicates a weak rescue of the phenotypes by POGLUT1D233E compared to POGLUT1WT. Mean &#177; standard deviation is shown. The differences in myotube lengths are statistically significant (n = 22-54). Mean &#177; standard deviation is shown; One-way Anova with Bonferroni&#180;s multiple comparisons test.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_7-A-F</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 7-A-F</infon>
    <infon key="sourcedata_figure_dir">Figure_7-A-F</infon>
    <passage>
      <offset>0</offset>
      <text>A-F Proliferation assays examined proliferating (PAX7+MyoD+, arrows), self-renewing (PAX7+ MyoD&#8722;, open arrows), and differentiating (PAX7&#8722; MyoD+, arrowheads) cells from D233E patients (n = 2), healthy controls (n = 3) and disease controls (n = 3) at 1, 4, and 8 days growing in proliferation medium. (A) shows representative images from day 8. The number of patientmyoblasts is lower than that of controls at all three time points, indicating a slower proliferation rate in patientmyoblasts (B), and accordingly, the percentage of proliferating cells (C) is smaller in the patient. (D) The percentage of self-renewing cells is small in patient&#180;s culture, reflecting a poor capacity for maintaining the pool of quiescent SCs. In addition, the percentage of PAX7+ cells (E) is smaller in patient&#180;s culture, similarly to what was found in adult D233E muscle (shown in Fig 5D). (F) The percentage of differentiating cells is higher in the patient. We examine proliferation capturing 7-12 randomly fields per day and condition (mean &#177; SEM is shown; Kruskal-Wallis with Dunn&#180;s multiple comparisons test; Scale bar, 50 &#181;m).</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_7-G-H-I</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 7-G-H-I</infon>
    <infon key="sourcedata_figure_dir">Figure_7-G-H-I</infon>
    <passage>
      <offset>0</offset>
      <text>G-I When myoblasts started to be confluent, the proliferation medium was replaced with differentiation medium, and the myoblasts started to fuse yielding myotubes, which were analyzed after four days of differentiation. (H) The fusion index, which measures the percentage of nuclei in myotubes with respect to the total number of nuclei in myogenic cells, was higher in D233E cultures than in controls. (I) Besides, myogenin showed increased expression in D233E myoblast cultures compared to controls. The data support that differentiation process is facilitated in patient&#180;s muscle. Data was collected from 3-10 randomly chosen areas per condition (mean &#177; SEM is shown; Kruskal-Wallis with Dunn&#180;s multiple comparisons test (H) and One-way Anova with Bonferroni&#180;s multiple comparisons test (I); Scale bar, 50 &#181;m).</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_8-A-B-C</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 8-A-B-C</infon>
    <infon key="sourcedata_figure_dir">Figure_8-A-B-C</infon>
    <passage>
      <offset>0</offset>
      <text>A-C We overexpressed GFP-tagged NICD in immortalized primary myoblasts to rescue the features displayed by immortalized D233E myoblasts. (B) We analyzed the proliferation at 1, 3 and 5 days, and proliferation rate in patient-LV-NICD-GFP reached the level observed in control-LV-GFP, which were higher than in patient-LV-GFP. (C) However, the percentage of PAX7+cells in patient-LV-NICD-GFP showed the same reduced value as in patient-LV-GFP, which were significantly lower than in control-LV-GFP. The majority of control myoblasts were proliferating cells (PAX7+ MyoD+, arrows), with no quiescent cells and few differentiating cells detected. Data were collected from n = 2 independent assays (5-8 images per condition). Mean &#177; SEM is shown; One-way Anova with Tukey multiple comparisions test (B) and Kruskal-Wallis with Dunn&#180;s multiple comparisons test (C); Scale bar, 50 &#181;m).</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_8-D-E-F</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 8-D-E-F</infon>
    <infon key="sourcedata_figure_dir">Figure_8-D-E-F</infon>
    <passage>
      <offset>0</offset>
      <text>D-F As previously described in patient's primary myoblasts, patient-LV-GFPmyoblasts showed a striking facilitated differentiation compared to control-LV-GFP-myoblasts. This phenotype fully disappeared in patient-LV-GFP-NICD myoblasts, as quantification of the fusion index (E), and myogenin expression (F) demonstrated. The data support a pathogenic role for Notch inhibition on the altered differentiation in our patients. Data were collected from n = 3 independent assays (13-17 images per condition). Mean &#177; SEM is shown; Kruskal-Wallis with Dunn&#180;s multiple comparisons test; Scale bar, 50 &#181;m).</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_9-A</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 9-A</infon>
    <infon key="sourcedata_figure_dir">Figure_9-A</infon>
    <passage>
      <offset>0</offset>
      <text>A Immortalized primary myoblasts from a healthy control showed a progressive pattern of &#945;-dystroglycan glycosylation during five days of differentiation (D0-D5), as has been previously described by Goddeeris et al. Immortalized primary myoblasts from patients displayed an irregular pattern of glycosylation, with a final level of glycosylated &#945;-dystroglycan that was lower than control.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_9-B</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 9-B</infon>
    <infon key="sourcedata_figure_dir">Figure_9-B</infon>
    <passage>
      <offset>0</offset>
      <text>B &#945;-dystroglycan glycosylation of infected immortalized myoblasts from patient-LV-NICD-GFP at differentiation day 5 (D5) showed a striking reduction, in line with the strong inhibition of myotubes formation and differentiation induced by NICD overexpression. &#945;-dystroglycan in myoblasts from patient-LV-GFP showed a reduction of glycosylation compared to control-LV-GFP at D5, similar to the results obtained in the adult muscle from patients (Fig. 2).</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_9-C-D</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 9-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_9-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>C-D C2C12 myogenic cells showed a reduced level of glycosylated &#945;-dystroglycan when the Notch signaling inhibitor DAPT or LY3039478 was added to the differentiation medium. This indicates that reducing Notch signaling can affect &#945;-dystroglycan glycosylation in wild-type C2C12 myoblasts cells, which do not harbor any known mutations in &#945;-dystroglycan glycosyltransferases or Poglut1.</text>
    </passage>
  </document>
  <document>
    <id>5090660 Figure_9-E-F</id>
    <infon key="sourcedata_document">2296</infon>
    <infon key="doi">10.15252/emmm.201505815</infon>
    <infon key="pmc_id">5090660</infon>
    <infon key="figure">Figure 9-E-F</infon>
    <infon key="sourcedata_figure_dir">Figure_9-E-F</infon>
    <passage>
      <offset>0</offset>
      <text>E-F qRT-PCR experiments show that upon DAPT or LY3039478 treatment, a remarkable decrease in Hes1 mRNA is induced in C2C12 cells during differentiation.</text>
    </passage>
  </document>
</collection>
